company background image
1877 logo

Shanghai Junshi Biosciences SEHK:1877 Stock Report

Last Price

HK$12.24

Market Cap

HK$26.6b

7D

-6.6%

1Y

-32.1%

Updated

21 Dec, 2024

Data

Company Financials +

Shanghai Junshi Biosciences Co., Ltd.

SEHK:1877 Stock Report

Market Cap: HK$26.6b

1877 Stock Overview

A biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. More details

1877 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 29.55% per year

Trading at good value compared to peers and industry

Risk Analysis

Currently unprofitable and not forecast to become profitable over the next 3 years


My Notes

Capture your thoughts, links and company narrative

Shanghai Junshi Biosciences Co., Ltd. Competitors

Sichuan Kelun-Biotech Biopharmaceutical

SEHK:6990

HK$39.8b

InnoCare Pharma

SEHK:9969

HK$12.4b

RemeGen

SEHK:9995

HK$14.8b

3SBio

SEHK:1530

HK$14.2b

Price History & Performance

Summary of share price highs, lows and changes for Shanghai Junshi Biosciences
Historical stock prices
Current Share PriceHK$12.24
52 Week HighHK$21.70
52 Week LowHK$9.17
Beta0.41
1 Month Change-5.70%
3 Month Change15.47%
1 Year Change-32.08%
3 Year Change-73.68%
5 Year Change-55.73%
Change since IPO-48.46%

Recent News & Updates

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%

Oct 14
Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%

Recent updates

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%

Oct 14
Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Price Is Right But Growth Is Lacking After Shares Rocket 35%

Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Sep 30
Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Are Not Doing Enough For Some Investors

Aug 29
Shanghai Junshi Biosciences Co., Ltd.'s (HKG:1877) Revenues Are Not Doing Enough For Some Investors

Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?

Jun 28
Shanghai Junshi Biosciences (HKG:1877) Has Debt But No Earnings; Should You Worry?

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth

May 06
Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Fly 27% But Investors Aren't Buying For Growth

Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Mar 22
Is Shanghai Junshi Biosciences (HKG:1877) Using Debt Sensibly?

Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%

Jan 26
Risks Still Elevated At These Prices As Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Dive 29%

Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Dec 17
Is Shanghai Junshi Biosciences (HKG:1877) A Risky Investment?

Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?

Nov 20
Is Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Trading At A 38% Discount?

Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?

Sep 05
Health Check: How Prudently Does Shanghai Junshi Biosciences (HKG:1877) Use Debt?

Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

May 22
Revenues Not Telling The Story For Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate

May 01
Shanghai Junshi Biosciences Co., Ltd. (HKG:1877) Shares Could Be 35% Below Their Intrinsic Value Estimate

A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Jan 16
A Look At The Intrinsic Value Of Shanghai Junshi Biosciences Co., Ltd. (HKG:1877)

Shareholder Returns

1877HK BiotechsHK Market
7D-6.6%-3.9%-0.5%
1Y-32.1%-5.7%19.9%

Return vs Industry: 1877 underperformed the Hong Kong Biotechs industry which returned -5.7% over the past year.

Return vs Market: 1877 underperformed the Hong Kong Market which returned 19.9% over the past year.

Price Volatility

Is 1877's price volatile compared to industry and market?
1877 volatility
1877 Average Weekly Movement11.6%
Biotechs Industry Average Movement11.1%
Market Average Movement8.8%
10% most volatile stocks in HK Market18.6%
10% least volatile stocks in HK Market4.1%

Stable Share Price: 1877 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1877's weekly volatility (12%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20122,532Cong Liwww.junshipharma.com

Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of China.

Shanghai Junshi Biosciences Co., Ltd. Fundamentals Summary

How do Shanghai Junshi Biosciences's earnings and revenue compare to its market cap?
1877 fundamental statistics
Market capHK$26.62b
Earnings (TTM)-HK$1.92b
Revenue (TTM)HK$1.90b

6.3x

P/S Ratio

-6.3x

P/E Ratio

Is 1877 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1877 income statement (TTM)
RevenueCN¥1.79b
Cost of RevenueCN¥622.89m
Gross ProfitCN¥1.16b
Other ExpensesCN¥2.97b
Earnings-CN¥1.80b

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.83
Gross Margin65.15%
Net Profit Margin-100.90%
Debt/Equity Ratio43.8%

How did 1877 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 21:25
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Junshi Biosciences Co., Ltd. is covered by 19 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Congmin YuanCitic Securities Co., Ltd.
Tan Huan GanCitic Securities Co., Ltd.
Muk Tsz YungCitigroup Inc